X
<
1
SuperValu Cruises past Analyst Expectations, Still Sinks

SuperValu (SVU) reported adjusted EPS of $0.46, beating the consensus by $0.10. Total sales from continuing operations stood at $3.8 billion—35% higher YoY.

kmis-adjusted-eps-vs-estimates-2-1
Kinder Morgan’s 3Q17 Results Met Analysts' Expectations

Kinder Morgan reported its 3Q17 results on October 18, 2017. It reported an adjusted EPS of $0.15, which was in-line with analysts’ consensus estimates.

Asian
Pre-Market Report: Global Markets Are Stable on October 20

On October 20, the Shanghai Composite Index closed at 3,378.65 after rising 0.25%. The SPDR S&P China ETF (GXC) fell 1.7% on October 19, 2017.

sP-500-1
Highs and Lows: Wall Street's Performance on October 19

After rising for five consecutive trading weeks, the S&P 500 started this week on a stronger note. It rose in the first three trading days of the week.

RECENT Healthcare RESEARCH

Chart-01-1
What's Driving Incyte Now?

Incyte reported revenues of ~$326.4 million for 2Q17, compared with ~$246.3 million for 2Q16.

Chart-01-EPS-1
What's Driving Allergan’s Valuation?

Allergan reported an 8.8% increase in its 2Q17 revenues to $4.0 billion as compared to $3.7 billion in 2Q16.

Graph-1-6-1
What Jazz Pharmaceuticals Investors Are Watching in 2017

JAZZ is now engaged in patent litigations involving Xyrem in the US with four other generic players.

PROJECTIONS
What Investors Can Expect from Medtronic’s Fiscal 1Q18 Results

In fiscal 4Q17, Medtronic’s revenue came in at $7.9 billion, representing YoY (year-over-year) growth of ~5%.

Graph-1-4-1
Fresenius Medical Care in 2H17: Revenue Growth, Dialysis Products

In 1H17, Fresenius Medical Care (FMS) reported revenues close to 9.0 billion euros, which represents 14% YoY growth. At the end of 2Q17, the company operated 3,690 dialysis clinics around the world.

Chart-01-Val-1
What's Driving Sanofi's Post-2Q17 Valuation

Sanofi (SNY), one of the world’s largest pharmaceutical companies, reported operational growth of 5.5% to reach revenue of 8.7 billion euros in 2Q17.

EPS-estimates-1
Dentsply Sirona Reported Disappointing 2Q17 Results

Dentsply Sirona (XRAY) reported its 2Q17 earnings on August 9. The company earned revenues of ~$992.7 million, registering a year-over-year decline of ~2.9%.

Analysts-recommendation-2-1
Where Amgen Stands after 2Q17

Of the 24 analysts covering Amgen, four have recommended a “strong buy” for the stock, while six have recommended a “buy.”

Graph-1-2-1
Why Analysts Are Lining Up for Align Technology

Of the 13 analysts covering Align Technology in August 2017, eight rated the company a “strong buy,” and five rated it a “buy.”

analyst-recommendations-1
The New Varian: A Leaner, Meaner Medical Machine Company

With the spin-off of its Imaging Components business, Varian Medical Systems (VAR) is now more aligned with its core capabilities. In this series, we’ll discuss the company’s dynamics after the Varex spin-off.

Chart-01-Rev-EPS-1
What's Driving Pfizer’s Valuation after 2Q17 Earnings

Pfizer (PFE) is one of the largest pharmaceutical companies by revenue. It reported a 2% decline in revenues, to $12.89 billion in 2Q17 from $13.15 billion in 2Q16.

Graph-1-1
Should We Pay Attention to Alexion Pharmaceuticals in August?

In 2Q17, Alexion Pharmaceuticals (ALXN) reported revenues close to $912.0 million, which is a YoY (year-over-year) rise of 21.0%.

Analysts-recommendation-1
How Is AbbVie Positioned after 2Q17?

Twenty-one analysts were tracking AbbVie in August 2017. Three analysts suggested a “strong buy,” while seven suggested a “buy.”

rvenue-estimates-1
Better Aligned Oncology Technology Giant

Varian Medical Systems (VAR) reported its 3Q17 earnings on July 26, 2017. It reported revenues of $662.4 million, a rise of ~3.0% on a YoY basis.

Grph-10-1
Edwards Lifesciences: Growth Drivers, Surgical Aortic Valve Space

In its 2Q17 earnings conference call, Edwards Lifesciences (EW) projected 2017 adjusted EPS to fall to $3.65–$3.85, which is higher than the previous $3.43–$3.55.

Analysts-reco-1
Gilead Sciences Witnessed High Revenue Growth in 2Q17

Twenty-five analysts covered Gilead Sciences (GILD) in July 2017. One analyst recommended a “strong buy,” ten analysts recommended a “buy,” and 14 analysts recommended a “hold” on the stock.

Graph-1-7-1
Should Investors Be Interested in Edwards Lifesciences in 2017?

In 2Q17, Edwards Lifesciences (EW) reported revenues close to $842 million. The company reported underlying year-over-year revenue growth of ~15% in 2Q17.

Chart-01-Rev-1
GlaxoSmithKline Continues Its Growth Trend in 2Q17

In its earnings release on July 26, GlaxoSmithKline (GSK) reported 12% growth to ~7.3 billion pounds in its 2Q17 revenues. GSK surpassed analysts’ estimates for revenues and earnings per share.

Chart-01-EPS-5-1
What to Expect from Pfizer’s 2Q17 Earnings?

Pfizer (PFE) is set to release its 2Q17 earnings on August 1, 2017. Analysts estimate earnings per share of $0.66 on revenues of ~$13.1 billion for 2Q17.

Chart-01-Rev-2-1
Must-Read Notes on Bristol-Myers Squibb’s 2Q17 Earnings

Bristol-Myers Squibb’s top line rose nearly 6% to ~$5.1 billion in 2Q17 due to operational growth of 7% in its revenue.

X

Please select a profession that best describes you: